BiomX Inc. (PHGE-UN)
USD 0.9
(-5.26%)
USD 0.9
(-5.26%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 58.15 Million USD | 27.73% |
| 2022 | 45.53 Million USD | -41.62% |
| 2021 | 77.99 Million USD | 10.84% |
| 2020 | 70.36 Million USD | -23.62% |
| 2019 | 92.12 Million USD | 103.22% |
| 2018 | 45.33 Million USD | 224.02% |
| 2017 | 13.99 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 68.61 Million USD | -15.91% |
| 2024 Q1 | 81.6 Million USD | 40.32% |
| 2023 FY | 58.15 Million USD | 27.73% |
| 2023 Q3 | 33.05 Million USD | -19.87% |
| 2023 Q1 | 41.4 Million USD | -9.06% |
| 2023 Q2 | 41.25 Million USD | -0.37% |
| 2023 Q4 | 58.15 Million USD | 75.93% |
| 2022 Q4 | 45.53 Million USD | -12.27% |
| 2022 FY | 45.53 Million USD | -41.62% |
| 2022 Q3 | 51.9 Million USD | -11.1% |
| 2022 Q2 | 58.38 Million USD | -15.07% |
| 2022 Q1 | 68.74 Million USD | -11.86% |
| 2021 Q1 | 67.06 Million USD | -4.69% |
| 2021 Q4 | 77.99 Million USD | -4.66% |
| 2021 Q3 | 81.79 Million USD | 32.69% |
| 2021 Q2 | 61.64 Million USD | -8.07% |
| 2021 FY | 77.99 Million USD | 10.84% |
| 2020 Q3 | 75.15 Million USD | -4.03% |
| 2020 Q1 | 84.46 Million USD | -8.32% |
| 2020 Q4 | 70.36 Million USD | -6.37% |
| 2020 FY | 70.36 Million USD | -23.62% |
| 2020 Q2 | 78.31 Million USD | -7.28% |
| 2019 Q4 | 92.12 Million USD | 29.37% |
| 2019 Q3 | 71.2 Million USD | -0.58% |
| 2019 Q2 | 71.61 Million USD | 0.38% |
| 2019 Q1 | 71.35 Million USD | 0.61% |
| 2019 FY | 92.12 Million USD | 103.22% |
| 2018 Q3 | 114.33 Thousand USD | 0.0% |
| 2018 FY | 45.33 Million USD | 224.02% |
| 2018 Q4 | 70.92 Million USD | 61930.87% |
| 2017 FY | 13.99 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 19.38 Million USD | -200.067% |
| Ampio Pharmaceuticals, Inc. | 5.73 Million USD | -913.877% |
| Armata Pharmaceuticals, Inc. | 109.96 Million USD | 47.114% |
| Actinium Pharmaceuticals, Inc. | 81.44 Million USD | 28.595% |
| Azitra, Inc. | 5.11 Million USD | -1036.862% |
| Can-Fite BioPharma Ltd. | 9.98 Million USD | -482.2% |
| Chromocell Therapeutics Corporation | 96.39 Thousand USD | -60233.434% |
| Calidi Biotherapeutics, Inc. | 10.01 Million USD | -480.457% |
| CEL-SCI Corporation | 30.52 Million USD | -90.499% |
| iBio, Inc. | 28.73 Million USD | -102.394% |
| Lineage Cell Therapeutics, Inc. | 101.01 Million USD | 42.431% |
| MAIA Biotechnology, Inc. | 7.56 Million USD | -668.563% |
| Matinas BioPharma Holdings, Inc. | 65.57 Million USD | 11.318% |
| Navidea Biopharmaceuticals, Inc. | 4.37 Million USD | -1230.312% |
| NovaBay Pharmaceuticals, Inc. | 9.03 Million USD | -543.746% |
| NanoViricides, Inc. | 12.82 Million USD | -353.534% |
| Oragenics, Inc. | 4.96 Million USD | -1071.004% |
| BiomX Inc. | 58.15 Million USD | 0.0% |
| Protalix BioTherapeutics, Inc. | 84.43 Million USD | 31.123% |
| Palatin Technologies, Inc. | 10.74 Million USD | -441.376% |
| Scorpius Holdings, Inc. | 51.03 Million USD | -13.947% |